Sanofi-Aventis‘s new breast cancer drug BSI-201 could garner sales of up to $1.7bn by 2018 through markets in the US and abroad, according to a new report by Decision Resources.

According to the report, good overall survival rates demonstrated by the poly ADP-ribose polymerase (PARP) inhibitor in clinical trials and the need for novel targeted agents in this setting are expected to steal significant market share from Avastin, marketed by Roche, Genentech and Chugai.

The report envisages significant uptake in the triple negative breast cancer drug market in the US, France, Germany, Italy, Spain, the UK and Japan following its launch in 2012 in the US and Europe and in Japan in 2014.

The report also identifies BSI-201, and other key PARP inhibitors in development such AstraZeneca‘s Olaparib and Pfizer’s AG-014699 as key market players.

Decision Resources analyst Niamh Murphy said that the inhibition of PARP has emerged as a novel therapeutic strategy in DNA repair-deficient tumours.

“Studies suggest that combining PARP inhibition with DNA-damaging chemotherapy or radiation may have a synergistic or enhanced effect,” Murphy said.